You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 137 No. 12, December 1983 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  CLINICAL MEMORANDA
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on Web of Science (5)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Pharmacodynamics and Kinetics of Cimetidine in a Premature Newborn

JACOB V. ARANDA, MD, PHD; EUGENE W. OUTERBRIDGE, MD; JEROME J. SCHENTAG, PHARMD

Am J Dis Child. 1983;137(12):1207.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Cimetidine, an H2 receptor antagonist, is currently widely used to block gastric acid secretions in adult patients with peptic ulcers and to prevent stress ulceration and subsequent bleeding in critically ill or traumatized patients.1 It has also been used in newborns,2 despite lack of information on the pharmacologic effects and kinetic disposition of this drug in this age group. We, therefore, report the plasma elimination of this drug and its effect on gastric acid secretions in a premature neonate.

Report of a Case.—A 660-g female infant was born at 25 weeks' gestation. The first three weeks of life were complicated by severe apnea, bradycardia, and respiratory distress requiring mechanical ventilation. Congestive heart failure caused by a patent ductus arteriosus was also noted; it responded to diuretics and two courses of indomethacin and chloroquine phosphate. She received total parenteral nutrition. Impaired renal function was noted, presumably caused . . . [Full Text PDF of this Article]


Author Affiliations



Montreal Children's Hospital Montreal; State University of New York Buffalo



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1983 American Medical Association. All Rights Reserved.